286 related articles for article (PubMed ID: 26655303)
1. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
Wood M; Ates A; Andre VM; Michel A; Barnaby R; Gillard M
Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
[TBL] [Abstract][Full Text] [Related]
3. The First Negative Allosteric Modulator for Dopamine D
Rossi M; Fasciani I; Marampon F; Maggio R; Scarselli M
Mol Pharmacol; 2017 Jun; 91(6):586-594. PubMed ID: 28265019
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
[TBL] [Abstract][Full Text] [Related]
5. Discovery of D1 Dopamine Receptor Positive Allosteric Modulators: Characterization of Pharmacology and Identification of Residues that Regulate Species Selectivity.
Lewis MA; Hunihan L; Watson J; Gentles RG; Hu S; Huang Y; Bronson J; Macor JE; Beno BR; Ferrante M; Hendricson A; Knox RJ; Molski TF; Kong Y; Cvijic ME; Rockwell KL; Weed MR; Cacace AM; Westphal RS; Alt A; Brown JM
J Pharmacol Exp Ther; 2015 Sep; 354(3):340-9. PubMed ID: 26109678
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
[TBL] [Abstract][Full Text] [Related]
7. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
Gackenheimer SL; Schaus JM; Gehlert DR
J Pharmacol Exp Ther; 1995 Sep; 274(3):1558-65. PubMed ID: 7562534
[TBL] [Abstract][Full Text] [Related]
8. Quinpirole-induced 50 kHz ultrasonic vocalization in the rat: role of D2 and D3 dopamine receptors.
Brudzynski SM; Komadoski M; St Pierre J
Behav Brain Res; 2012 Jan; 226(2):511-8. PubMed ID: 22015714
[TBL] [Abstract][Full Text] [Related]
9. Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.
Aloisi G; Silvano E; Rossi M; Millan MJ; Maggio R
Neuropharmacology; 2011; 60(2-3):439-45. PubMed ID: 21035472
[TBL] [Abstract][Full Text] [Related]
10. Distinctive binding properties of the negative allosteric modulator, [
Fasciani I; Pietrantoni I; Rossi M; Mannoury la Cour C; Aloisi G; Marampon F; Scarselli M; Millan MJ; Maggio R
Eur J Pharmacol; 2018 Jan; 819():181-189. PubMed ID: 29223348
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats.
Jantschak F; Brosda J; Franke RT; Fink H; Möller D; Hübner H; Gmeiner P; Pertz HH
J Pharmacol Exp Ther; 2013 Oct; 347(1):57-68. PubMed ID: 23863695
[TBL] [Abstract][Full Text] [Related]
12. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
[TBL] [Abstract][Full Text] [Related]
13. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
[TBL] [Abstract][Full Text] [Related]
14. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
[TBL] [Abstract][Full Text] [Related]
15. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors.
McCormick PN; Wilson VS; Wilson AA; Remington GJ
Pharmacol Res; 2013 Apr; 70(1):66-71. PubMed ID: 23327779
[TBL] [Abstract][Full Text] [Related]
16. Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors.
Depoortère R; Bardin L; Rodrigues M; Abrial E; Aliaga M; Newman-Tancredi A
Behav Pharmacol; 2009 Jul; 20(4):303-11. PubMed ID: 19584712
[TBL] [Abstract][Full Text] [Related]
17. Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors.
Seeman P; Guan HC
Synapse; 2009 Aug; 63(8):705-9. PubMed ID: 19391149
[TBL] [Abstract][Full Text] [Related]
18. Identification of Positive Allosteric Modulators of the D
Luderman KD; Conroy JL; Free RB; Southall N; Ferrer M; Sanchez-Soto M; Moritz AE; Willette BKA; Fyfe TJ; Jain P; Titus S; Hazelwood LA; Aubé J; Lane JR; Frankowski KJ; Sibley DR
Mol Pharmacol; 2018 Oct; 94(4):1197-1209. PubMed ID: 30068735
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
20. Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer.
Bonaventura J; Navarro G; Casadó-Anguera V; Azdad K; Rea W; Moreno E; Brugarolas M; Mallol J; Canela EI; Lluís C; Cortés A; Volkow ND; Schiffmann SN; Ferré S; Casadó V
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):E3609-18. PubMed ID: 26100888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
